13F filer · CIK 1697748 ↗
ARK Invest
You are looking at Q4 2023. See the latest, Q2 2026 →
Reported value
$16.89B
+29% on the quarter before
Positions
223
2 new · 5 sold out
Top 10
48.7%
of the value
Est. gain
+$3.35B
on stocks held all quarter
Est. return
+27.2%
on those stocks since Q3 2023
Positions as of Dec 31, 2023, from ARK Invest's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q3 2023. Striped tiles are options.
Largest buys
Since Q3 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- The Trade Desk~$142.4MAdded · 0.1% → 0.9%+1,979,319 shares
- Recursion Pharmaceuticals Inc~$135.8MAdded · 0.4% → 1.2%+13,777,689 shares
- Proshares Bitcoin Strategy ETF~$93.2MNew · 0.0% → 0.6%+4,549,207 shares
- Crispr Therapeutics Ag~$85.9MAdded · 2.5% → 3.2%+1,372,986 shares
- Block~$77.4MAdded · 3.7% → 5.4%+1,000,514 shares
- 10x Genomics Inc~$58.6MAdded · 0.9% → 1.3%+1,047,827 shares
- Zoom~$56.2MAdded · 5.4% → 4.7%+781,663 shares
- Pacific Biosciences Of Califor~$45.9MAdded · 1.9% → 2.0%+4,681,833 shares
- Intellia Therapeutics Inc~$44.6MAdded · 2.4% → 2.1%+1,463,820 shares
- Pinterest Inc~$32.3MAdded · 0.1% → 0.3%+872,016 shares
Largest sells
Since Q3 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Coinbase~$348.5MCut · 6.1% → 8.9%−2,003,881 shares
- Grayscale Bitcoin Trust Btc~$108.1MSold out · 0.8% → 0.0%−5,630,602 shares
- UiPath~$95.8MCut · 6.2% → 6.4%−3,855,679 shares
- Roku Inc~$83.5MCut · 5.6% → 5.2%−910,941 shares
- Draftkings Inc~$81.4MCut · 3.3% → 2.6%−2,310,617 shares
- Shopify Inc~$73.6MCut · 2.9% → 2.8%−944,654 shares
- Tesla~$68.6MCut · 7.8% → 5.6%−276,132 shares
- Nvidia~$38.0MCut · 0.7% → 0.4%−76,712 shares
- Ionis Pharmaceuticals Inc~$23.3MCut · 0.8% → 0.6%−461,311 shares
- Exact Sciences Corp~$18.3MCut · 3.3% → 2.6%−248,038 shares
Holdings
As of Dec 31, 2023. Changes are in shares against Sep 30, 2023, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CoinbaseCommon Stock · shares −19% · price +131.6% | 8.9% | $1.50B | +$850.0M | ||||||||
| UiPathCommon Stock · shares −8.1% · price +45.2% | 6.4% | $1.08B | +$336.0M | ||||||||
| TeslaCommon Stock · shares −6.8% · price −0.7% | 5.6% | $944.9M | −$6.6M | ||||||||
| BlockCommon Stock · shares +9.2% · price +74.8% | 5.4% | $919.5M | +$360.3M | ||||||||
| Roku IncCommon Stock · shares −8.7% · price +29.8% | 5.2% | $873.4M | +$200.8M | ||||||||
| ZoomCommon Stock · shares +7.7% · price +2.8% | 4.7% | $788.5M | +$20.1M | ||||||||
| RobloxCommon Stock · shares −0.6% · price +57.9% | 3.2% | $544.4M | +$199.5M | ||||||||
| TwilioCommon Stock · shares −0.03% · price +29.6% | 3.2% | $541.0M | +$123.6M | ||||||||
| Crispr Therapeutics AgCommon Stock · shares +19% · price +37.9% | 3.2% | $534.4M | +$123.3M | ||||||||
| Unity Software IncCommon Stock · shares +6.2% · price +30.3% | 3.0% | $498.4M | +$109.0M | ||||||||
| Shopify IncCommon Stock · shares −14% · price +42.8% | 2.8% | $468.2M | +$140.2M | ||||||||
| Teladoc Health IncCommon Stock · shares +4.5% · price +15.9% | 2.7% | $457.4M | +$60.1M | ||||||||
| Exact Sciences CorpCommon Stock · shares −3.9% · price +8.4% | 2.6% | $446.3M | +$34.7M | ||||||||
| RobinhoodCommon Stock · shares +6.4% · price +29.9% | 2.6% | $445.1M | +$96.2M | ||||||||
| Draftkings IncCommon Stock · shares −16% · price +19.7% | 2.6% | $434.2M | +$71.6M | ||||||||
| Intellia Therapeutics IncCommon Stock · shares +15% · price −3.6% | 2.1% | $348.0M | −$11.2M | ||||||||
| Pacific Biosciences Of CaliforCommon Stock · shares +16% · price +17.5% | 2.0% | $338.5M | +$43.5M | ||||||||
| Ginkgo Bioworks Holdings IncCommon Stock · shares +9.0% · price −6.6% | 2.0% | $335.6M | −$21.9M | ||||||||
| Twist Bioscience CorpCommon Stock · shares +6.3% · price +81.9% | 1.6% | $265.9M | +$112.6M | ||||||||
| Pagerduty IncCommon Stock · shares +8.1% · price +2.9% | 1.6% | $264.2M | +$7.0M | ||||||||
| Beam Therapeutics IncCommon Stock · shares +6.9% · price +13.2% | 1.5% | $255.7M | +$27.8M | ||||||||
| 10x Genomics IncCommon Stock · shares +35% · price +35.7% | 1.3% | $226.2M | +$44.0M | ||||||||
| Veracyte IncCommon Stock · shares +0.8% · price +23.2% | 1.2% | $210.6M | +$39.3M | ||||||||
| Recursion Pharmaceuticals IncCommon Stock · shares +200% · price +28.9% | 1.2% | $203.7M | +$15.2M | ||||||||
| PalantirCommon Stock · shares +16% · price +7.3% | 1.1% | $187.8M | +$11.0M | ||||||||
| Total · 223 positions | 100% | $16.89B | +$3.35B |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q3 2023 to Q4 2023: 220 stocks held throughout, up $3.35B (+27.2%).
- Coinbase+$850.0M+132%
- Block+$360.3M+75%
- UiPath+$336.0M+45%
- Roku Inc+$200.8M+30%
- Roblox+$199.5M+58%
- 2u Inc−$11.9M−50%
- Markforged Holding Corp−$11.9M−43%
- Repare Therapeutics Inc−$12.5M−40%
- Velo3d Inc−$15.5M−75%
- Ginkgo Bioworks Holdings Inc−$21.9M−7%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $15.40B+20% | SEC ↗ |
| Q1 2026 | May 12, 2026 | $12.86B−15% | SEC ↗ |
| Q4 2025 | Feb 11, 2026 | $15.07B−10% | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | $16.80B+23% | SEC ↗ |
| Q2 2025 | Jul 30, 2025 | $13.64B+37% | SEC ↗ |
| Q1 2025 | May 7, 2025 | $9.99B−17% | SEC ↗ |
| Q4 2024 | Feb 4, 2025 | $12.01B+10% | SEC ↗ |
| Q3 2024 | Oct 31, 2024 | $10.93B−3% | SEC ↗ |
| Q2 2024 | Jul 26, 2024 | $11.27B−22% | SEC ↗ |
| Q1 2024 | Apr 18, 2024 | $14.44B−14% | SEC ↗ |
| Q4 2023 | Jan 17, 2024 | $16.89B+29% | SEC ↗ |
| Q3 2023 | Oct 18, 2023 | $13.07B−13% | SEC ↗ |
| Q2 2023 | Jul 10, 2023 | $15.10B+4% | SEC ↗ |
| Q1 2023 | Apr 17, 2023 | $14.55B+26% | SEC ↗ |
| Q4 2022 | Jan 24, 2023 | $11.54B−20% | SEC ↗ |
| Q3 2022 | Oct 17, 2022 | $14.35B−15% | SEC ↗ |
| Q2 2022 | Jul 11, 2022 | $16.91B−29% | SEC ↗ |
| Q1 2022 | Apr 18, 2022 | $23.96B−28% | SEC ↗ |
| Q4 2021 | Jan 28, 2022 | $33.08B−21% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $41.64B−23% | SEC ↗ |
| Q2 2021 | Aug 5, 2021 | $53.74B+7% | SEC ↗ |
| Q1 2021 | May 13, 2021 | $50.34B+34% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $37.59B+123% | SEC ↗ |
| Q3 2020 | Oct 30, 2020 | $16.86B+81% | SEC ↗ |
| Q2 2020 | Aug 11, 2020 | $9.30B+132% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $4.01B+1% | SEC ↗ |
| Q4 2019 | Jan 31, 2020 | $3.96B−13% | SEC ↗ |
| Q3 2019 | Nov 12, 2019 | $4.58B+15% | SEC ↗ |
| Q2 2019 | Jul 30, 2019 | $3.97B+13% | SEC ↗ |
| Q1 2019 | May 13, 2019 | $3.50B+42% | SEC ↗ |
| Q4 2018 | Feb 11, 2019 (amended) | $2.46B−26% | SEC ↗ |
| Q3 2018 | Nov 7, 2018 | $3.31B+21% | SEC ↗ |
| Q2 2018 | Aug 7, 2018 | $2.73B+36% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $2.01B+60% | SEC ↗ |
| Q4 2017 | Feb 12, 2018 | $1.26B+53% | SEC ↗ |
| Q3 2017 | Nov 9, 2017 | $819.3M+60% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $513.6M+48% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $346.9M+26% | SEC ↗ |
| Q4 2016 | Feb 13, 2017 | $274.9M | SEC ↗ |